A champion of leadership education at HKS, Gergen leaves a lasting legacy as a political analyst, adviser, and leadership ...

November 30, 2023, Video: "The role of immigration in shaping the nation's economy remains a hotly contested area of debate. Factors such as the real economic benefits of high-skilled versus ...

May 2020, Paper, "Impact investing has grown significantly over the past 15 years. From a niche investing segment with only $25 billion AUM in 2013 (WEF 2013), it experienced double-digit growth and ...

June 15, 2021, Video: "Rebecca Henderson teaches at the Harvard Business School, but she’s a vocal critic of “business as usual.” In fact, her scholarly research focuses on how we need to change ...

September 2, 2021, Video: "Renowned Harvard Business School professor Dr. John Kotter has studied, written, and lectured about leadership for decades. In his newest book, Change, Kotter dives into how ...

July 29, 2020, Paper, "Pledging patents as loan collateral has increased in advanced countries with the growth of intangibles in the value of firms. Despite China's less sophisticated market in ...

Research from the Shift Project examines the effects of paid sick leave laws.

April 18, 2025, Paper: "We examine whether information in the 10-K Business Description section on f irms’ development and deployment of climate solution products and services can be used to assess ...

October 29, 2020, Audio: "Does Zoom mean we all work from home? Will cities bounce back? Will San Francisco and New York fade and smaller cities grow? What problems are the policies causing and can ...

August 2020, Paper: "China’s real estate has been a key engine of its sustained economic expansion. This paper argues, however, that even before the Covid-19 shock, a decades-long housing boom had ...

October 1, 2020, Paper: "From the technical analyses of wide ranges of scholars to the public discourse backlashes against globalization, there is a huge volume of work historicizing, quantifying, and ...

September/October 2021, Paper: "On November 30, 2020, Moderna Therapeutics announced that Phase III clinical trials for its messenger RNA vaccine demonstrated 95% protective efficacy against the ...